KDELR2 and osteogenesis imperfecta: In addition, known mutations in KDELR1 and KDELR2 are associated with lymphopenia and osteogenesis imperfecta, respectively, making KDEL receptor replacement an attractive therapeutic strategy for these conditions [87,88].